Quick answer: Irritable bowel syndrome affects 10–15% of Americans, GERD affects 20%, and SIBO (small intestinal bacterial overgrowth) — a frequently undiagnosed condition — is present in up to 78% of IBS patients. Functional gastroenterology identifies the root causes of these conditions — from hypochlorhydria driving SIBO, to impaired migrating motor complex, to dysbiosis-driven intestinal permeability — using breath testing, organic acids, comprehensive stool analysis, and GI-MAP testing, and treats them with targeted protocols rather than lifelong acid suppression or symptomatic medications.
Conventional gastroenterology excels at structural diagnosis — detecting cancer, inflammatory bowel disease, ulcers, and anatomical abnormalities — and deserves full credit for these achievements. But for the vast majority of patients presenting with IBS, GERD, bloating, constipation, or abdominal pain, conventional approaches focus on symptom management: PPIs for reflux, laxatives for constipation, antispasmodics for IBS pain. Functional gastroenterology starts upstream: why is the gut producing excess gas? Why is gastric emptying slowed? Why is the esophageal sphincter failing? The answers reveal addressable mechanisms, not just managed symptoms.
SIBO: The Undiagnosed Driver of IBS, Bloating, and Malabsorption
Small intestinal bacterial overgrowth occurs when bacteria normally confined to the colon colonize the small intestine, fermenting carbohydrates that should be absorbed before reaching the colon and producing hydrogen and/or methane gas that causes bloating, distension, and altered bowel habits. Pimentel et al. (2000, American Journal of Gastroenterology) showed 78% of IBS patients had abnormal lactulose hydrogen breath tests — placing SIBO as the likely driver of the majority of IBS cases. Subsequent studies confirmed positive breath test rates of 54–84% in IBS depending on testing protocol and diagnostic criteria. The Cedars-Sinai SIBO hypothesis explains IBS through three steps: food poisoning or gastroenteritis → cytolethal distending toxin B (CdtB) antibodies → anti-vinculin autoantibodies impairing interstitial cells of Cajal (the pacemaker cells driving the migrating motor complex) → SIBO.
Breath testing is the primary SIBO diagnostic tool: the lactulose hydrogen breath test and glucose hydrogen breath test each have distinct characteristics. Hydrogen-dominant SIBO (produced by Bacteroidetes and Firmicutes fermenting carbohydrates) causes loose stools/diarrhea in most cases. Methane-dominant SIBO (now reclassified as intestinal methanogen overgrowth, IMO, caused by Methanobrevibacter smithii) causes constipation — methane gas slows intestinal transit by 59% per part-per-million increase (Pimentel 2006). Hydrogen sulfide SIBO — produced by sulfate-reducing bacteria — causes diarrhea, brain fog, and the characteristic “rotten egg” odor not captured by standard breath tests; it requires the newer tri-gas breath test. Organic acids testing (urine) detects D-arabinitol (yeast/SIFO indicator) and bacterial metabolites that provide indirect evidence of small intestinal dysbiosis even when breath testing is equivocal.
SIBO treatment: rifaximin (550mg 3x/day × 14 days) is the best-studied antibiotic, achieving 49–87% eradication rates for hydrogen-dominant SIBO (Pimentel 2011 TARGET 1&2 trials). Methane/IMO requires rifaximin plus neomycin, or rifaximin plus metronidazole. Elemental diet (exclusive liquid nutrition absorbed in the proximal small bowel, starving the bacteria) achieves 80–84% normalization rates at 14 days and is the most evidence-based non-antibiotic treatment (Pimentel 2004). Herbal antimicrobials — berberine, oregano oil, allicin (from aged garlic), and neem — show comparable to rifaximin eradication rates in retrospective studies (Chedid 2014, Global Advances in Health and Medicine). Post-treatment prokinetics (low-dose naltrexone, prucalopride, erythromycin at prokinetic dose, iberogast) are essential to restore the MMC and prevent relapse — addressing the root-cause motility impairment.
Hypochlorhydria: The Hidden Root Cause of SIBO, GERD, and Malabsorption
Gastric acid (hydrochloric acid) performs five critical functions: protein digestion (denaturing proteins and activating pepsinogen to pepsin); mineral absorption (iron, zinc, calcium, and B12 all require acid for optimal absorption); antimicrobial barrier (gastric acid kills 99.9% of ingested pathogens, including Helicobacter pylori in normal-acid conditions); pyloric sphincter regulation (low pH triggers appropriate gastric emptying); and prevention of bacterial overgrowth (normal acid levels prevent retrograde bacterial colonization of the small intestine). Hypochlorhydria — reduced stomach acid production — simultaneously impairs all five functions.
The GERD paradox: most GERD is not caused by too much acid but by acid in the wrong place — driven by lower esophageal sphincter dysfunction, delayed gastric emptying (requiring fermentation pressure to force contents upward), and the burning sensations from even normal amounts of acid reaching a sensitized esophageal mucosa. Proton pump inhibitors reduce acid production and provide symptomatic relief, but do not address the underlying mechanisms — and chronic PPI use (>1 year) is associated with significant downstream consequences: small intestinal bacterial overgrowth (2–8-fold increased risk), C. difficile infection, community-acquired pneumonia, hypomagnesemia, hip fracture, B12 deficiency, iron deficiency, and increased all-cause mortality (multiple prospective studies). Functional GERD evaluation: check for H. pylori (causes hypochlorhydria), assess gastric motility, evaluate for hiatal hernia, test for SIBO, and measure betaine HCl tolerance as a functional assessment of stomach acid sufficiency.
H. pylori: The Stomach Pathogen That Changes Everything
Helicobacter pylori infects approximately 44% of the global population and 35% of Americans — making it one of the most prevalent bacterial infections worldwide. H. pylori colonizes the gastric mucosa, producing urease to neutralize local acid, stimulating cytokine production (IL-1β, IL-8, TNF-α) that damages the gastric lining, reducing somatostatin-producing D cells (which normally suppress gastrin), and driving hypergastrinemia that paradoxically causes hypochlorhydria in the antrum while elevating acid in the corpus. The result is chronic gastritis, peptic ulcer disease, and — with virulent CagA+/VacA+ strains — gastric adenocarcinoma (H. pylori is classified as a Group 1 carcinogen by the IARC).
Beyond gastric effects, H. pylori has systemic functional medicine implications: it drives iron deficiency anemia through occult GI blood loss and reduced iron absorption (multiple meta-analyses confirm higher anemia prevalence and improved iron status after eradication); impairs B12 absorption through reduced intrinsic factor secretion; is independently associated with ischemic heart disease (Longo et al. 2002, meta-analysis); may contribute to rosacea, urticaria, and Raynaud’s phenomenon through immune mechanisms; and creates the hypochlorhydria environment that promotes SIBO. Testing: urea breath test (most accurate non-invasive test, 96% sensitivity), stool antigen test, or endoscopic biopsy. Treatment: standard triple or quadruple therapy, with functional adjuncts — mastic gum (Huwez 1998, NEJM letter: 5 patients cured with mastic gum alone), bismuth, probiotics during treatment to reduce side effects and improve eradication rates (Zheng et al. 2013 meta-analysis: probiotics increase H. pylori eradication by 10–14%). Post-eradication: acid rebound is common (2–8 weeks), requiring temporary DGL licorice/zinc carnosine for mucosal healing, followed by reassessment of stomach acid sufficiency.
Intestinal Permeability (Leaky Gut): The Gateway to Systemic Inflammation
Intestinal permeability — the controlled passage of molecules across the gut epithelium — is maintained by tight junction proteins (claudins, occludin, ZO-1, ZO-2) connecting intestinal epithelial cells. When tight junctions are disrupted by inflammatory triggers, luminal bacteria, undigested food antigens, LPS, alcohol, NSAIDs, stress-induced mast cell degranulation, and zonulin (released by gliadin/gluten and certain bacteria), the gut becomes permeable to molecules that should not cross. The result: bacterial endotoxins (LPS) reaching the portal circulation, triggering hepatic TLR4 activation and systemic low-grade inflammation; dietary antigens crossing the barrier, triggering immune sensitization and food reactivity; and microbial metabolites entering circulation, driving distant organ inflammation.
The 4R (and now 5R) protocol for gut restoration: (1) Remove — pathogens (H. pylori, SIBO, parasites, Candida overgrowth), inflammatory foods (gluten, dairy, processed foods), NSAID use; (2) Replace — digestive insufficiency with betaine HCl, digestive enzymes, bile acid support; (3) Reinoculate — beneficial bacteria with targeted probiotics and diverse plant fiber; (4) Repair — gut lining with L-glutamine (4g/day), zinc carnosine, colostrum, deglycyrrhizinated licorice (DGL), and aloe vera; (5) Rebalance — lifestyle factors: stress reduction (cortisol directly increases gut permeability through mast cell activation), sleep optimization, and removing toxin exposures. Testing: lactulose/mannitol ratio (urine) or newer biomarkers including serum zonulin (controversial standardization issues), LPS-binding protein, and intestinal fatty acid binding protein (I-FABP).
Frequently Asked Questions About Functional Gastroenterology
How is functional gastroenterology different from conventional GI care?
Conventional gastroenterology prioritizes structural diagnosis (colonoscopy, endoscopy, imaging) and pharmacological symptom management. Functional gastroenterology uses these tools but adds mechanistic root-cause investigation: breath testing for SIBO, comprehensive stool analysis (GI-MAP) for dysbiosis and pathogens, organic acids testing for fungal overgrowth and metabolic byproducts, assessment of digestive sufficiency (enzymes, bile acids, stomach acid), testing for intestinal permeability, and food sensitivity evaluation. The goal is resolving the underlying mechanisms producing symptoms — not managing symptoms indefinitely with medications that create their own downstream problems.
What is the relationship between gut health and mental health?
The gut-brain axis is bidirectional and mechanistically profound. The enteric nervous system contains 500 million neurons — more than the spinal cord — and communicates with the brain via the vagus nerve (80% of signals travel upward, gut to brain), immune signaling (microbial metabolites influence microglial activation), and direct neurotransmitter production (95% of serotonin is produced in the gut by enterochromaffin cells). Gut dysbiosis drives neuroinflammation through LPS-mediated microglial activation; SIBO produces D-lactic acid and bacterial neurotoxins that cause brain fog and cognitive dysfunction; and tryptophan metabolism in the gut determines the balance between serotonin production and kynurenine pathway activation (associated with depression). Valles-Colomer et al. (2019, Nature Microbiology) found specific bacterial species — Coprococcus and Dialister — were consistently depleted in depression, while higher gut microbiome diversity correlated with better mental health outcomes.
What causes chronic constipation from a functional medicine perspective?
Chronic constipation has multiple functional medicine root causes that are frequently overlooked: methane-dominant SIBO (methane gas is a gut neurotoxin that slows transit); hypothyroidism (thyroid hormone is required for normal gut motility — addressing suboptimal thyroid function resolves constipation in many patients); magnesium deficiency (magnesium relaxes smooth muscle and draws water into the colon — magnesium oxide/glycinate is highly effective); dehydration; low-fiber diet; sedentary lifestyle; pelvic floor dysfunction (dyssynergia — requiring pelvic floor physical therapy rather than laxatives); histamine intolerance driving mast cell activation in the gut; and dysautonomia (vagal dysfunction reducing parasympathetic stimulation of colonic motility). Laxative dependency creates additional motility dysfunction and should be tapered, not perpetuated.
Is food sensitivity testing useful?
Food sensitivity testing (IgG antibodies) has significant controversy. IgG antibodies represent immune exposure, not necessarily pathological sensitivity — elevated IgG to a food means you eat it frequently, not necessarily that it harms you. However, in the context of intestinal permeability, IgG food reactivity panels can identify foods that are crossing the leaky gut and driving immune activation. The most clinically reliable approach remains the elimination diet — removing the most common reactive foods (gluten, dairy, corn, soy, eggs, peanuts, tree nuts, shellfish) for 3–6 weeks and conducting structured reintroduction to identify individual reactors. This can be guided by IgG testing to prioritize which foods to test, while recognizing that restoring gut barrier integrity often resolves food reactivities that were secondary to the leaky gut rather than primary sensitivities.
Integrating Functional Gastroenterology: The Clinical Approach
Comprehensive functional gastroenterology assessment begins with detailed symptom mapping (bloating timing — immediate after eating suggests SIBO vs. fermentation; constipation subtype — hard stools vs. incomplete evacuation vs. infrequency; reflux pattern — supine vs. upright), followed by appropriate testing: GI-MAP comprehensive stool analysis (quantitative PCR for pathogenic and commensal organisms, markers of inflammation like calprotectin and lactoferrin, zonulin, beta-glucuronidase, secretory IgA), SIBO breath testing (hydrogen + methane ± hydrogen sulfide), H. pylori testing, and food elimination/reintroduction protocol. Structural screening (colonoscopy, upper endoscopy) is appropriately coordinated with the gastroenterology team for age-appropriate cancer screening and to rule out structural disease.
Treatment is sequenced: address active infections first (H. pylori, SIBO, parasites), then restore digestive sufficiency, then repair gut barrier, then reinoculate with beneficial bacteria, and finally reintroduce foods removed during treatment. This sequence matters — probiotic supplementation in active SIBO can worsen symptoms; introducing fermentable fiber before SIBO is treated feeds the organisms causing symptoms. The entire protocol typically requires 3–6 months and substantially reduces or eliminates GI symptoms in the majority of patients who complete it. Monitoring with repeat breath testing and stool analysis 4–6 weeks post-treatment guides retreatment decisions. If you suffer from IBS, SIBO, chronic bloating, reflux, constipation, or unexplained digestive symptoms, and want a comprehensive root-cause evaluation, call The Private Practice at (810) 206-1402 to schedule your functional gastroenterology consultation.